News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Evaxion Presents New Preclinical Data Supporting EVX-V1 Cytomegalovirus Vaccine Programme
Monday, July 13, 2026Evaxion AS has presented new preclinical data supporting its cytomegalovirus CMV vaccine programme EVXV at the International Herpesvirus Workshop IHW in Montreal Canada
Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial for Idiopathic Pulmonary Fibrosis
Monday, July 13, 2026Celea Therapeutics has dosed the first patient in the global Phase SURPASSIPF trial evaluating deupirfenidone as a treatment for idiopathic pulmonary fibrosis IPF The study will compare deupirfenidone mg
Blue Earth Therapeutics doses first participant in Phase 1 trial of Actinium (²²⁵Ac) rhPSMA-10.1 Injection for advanced prostate cancer
Friday, July 10, 2026Blue Earth Therapeutics and University College London UCL have dosed the first participant in a Phase clinical trial evaluating Actinium Ac rhPSMA Injection an investigational prostatespecific membrane antigen
LEO Pharma reports positive Phase 2 trial results for tralokinumab in children with atopic dermatitis
Friday, July 10, 2026LEO Pharma has announced positive results from the Phase TRAPEDS trial which evaluated the pharmacokinetics and safety of tralokinumab in children aged to years with moderatetosevere atopic dermatitis
Roche receives CE Mark for blood test to identify tuberculosis infection
Friday, July 10, 2026Roche has received CE Mark approval for its Elecsys IGRA TB test expanding its tuberculosis TB diagnostics portfolio with a new blood test designed to identify tuberculosis infection TBI also known as latent TB in routine laboratory settings
Vertex Secures US FDA Approval for Expanded Use of CASGEVY in Young Children
Thursday, July 02, 2026Vertex Pharmaceuticals has received approval from the US Food and Drug Administration FDA to expand the use of CASGEVY exagamglogene autotemcel for patients aged two years and older with sickle cell disease
Nona Biosciences and Lonza Collaborate on BBB-Crossing Technology for CNS Drug Development
Thursday, July 02, 2026Nona Biosciences has entered into a strategic collaboration with Lonza to develop singledomain antibodybased bloodbrain barrier BBBcrossing technology for the treatment of central nervous system CNS diseases
